16 results about "Abnormal proteins" patented technology

The invention relates to the technical field of protein structure detection, in particular to an active collagen triple helix structure integrity detection method, which comprises the following steps: obtaining an active collagen detection solution to be detected, and centrifuging to obtain an initial structure detection solution; obtaining upper-layer liquid and bottom-layer liquid of the initial structure detection liquid, carrying out by-product detection, and recording a detection result; determining by-product interference parameters of the initial structure detection liquid so as to determine a protein structure abnormity tendency type; removing supernatant liquid of the initial structure detection liquid to obtain triple-helix structure analysis liquid, and determining the analysis mode of the triple-helix structure analysis liquid according to the protein structure abnormity tendency type of the initial structure detection liquid, so that the detection mode can be adaptively selected, and the triple-helix structure integrity of the active collagen can be accurately evaluated; the detection reliability is ensured, meanwhile, product waste is avoided, an effective monitoring means is provided for the collagen purification process, and the collagen purification efficiency and the product quality are improved.

The present invention relates to novel peptides and uses thereof, and more particularly to peptides having a length of 12 to 20 a.a. comprising an amino acid sequence designated as SEQ ID NO: 1 or 2, having the ability to inhibit the formation of abnormal protein aggregates, wherein 1 to 4 of the amino acids excluding glycine are L-type amino acids and the other amino acids are D-type amino acids.

Alternative splicing events in genes can lead to non-productive mRNA transcripts, which in turn can lead to abnormal protein expression, and therapeutic agents that can target alternative splicing events in genes can modulate the expression level of functional proteins in patients and / or inhibit abnormal protein expression. Such therapeutic agents can be used to treat conditions or diseases caused by protein deficiency.

The present invention provides a polypeptide that specifically recognizes structurally abnormal proteins generated in mammals due to misfolding or the like, and an agent for detecting or reducing structurally abnormal proteins that uses the polypeptide. The present invention relates to an agent for detecting structurally abnormal proteins, comprising as an active ingredient a polypeptide having structurally abnormal proteins-binding site which is a polypeptide consisting of the amino acid sequence represented by SEQ ID NO:2, or a polypeptide consisting of an amino acid sequence having 90% or more sequence identity with the amino acid sequence and having binding activity to structurally abnormal proteins, and an agent for reducing structurally abnormal proteins comprising as an active ingredient a polypeptide containing the structurally abnormal protein binding site and a ubiquitin ligase active site.

Bipartite molecules comprising a peptide affinity moiety and at least one charged moiety and uses thereof in reducing formation of abnormal protein aggregate and treating diseases associated with such abnormal protein aggregate, including neurodegenerative disease characterized by formation of protein aggregates.

The present invention relates to a novel peptide and its use, and more specifically, to a peptide having the ability to inhibit the formation of abnormal protein aggregates, having the ability to inhibit the formation of abnormal protein aggregates and autophagy activity against the protein aggregates, H-G-X 1 -X 2 -G-X 3 which comprises a structure of, and provides a novel peptide having a length of 4 to 10 amino acids and its use.

Described herein are polypeptide useful for identifying compound for modulating aberrant protein condensates. The polypeptide comprise a condensate-modulating protein, a first biomarker polypeptide, a barcoding biomarker polypeptide. When inside a cell, the non-natural polypeptide exist as multiple fragments, including a first fragment comprising the condensate-modulating protein and the first biomarker polypeptide, and a second fragment comprising the barcoding biomarker polypeptide. The barcoding biomarker polypeptide is uniquely associated with and identifies the cell expressing associated condensate-modulating protein. Also described is a polynucleotide encoding the non-natural polypeptide, a library of the polynucleotide, and a method of identifying compound for modulating aberrant protein condensates using the non-natural polypeptide, the construct, and / or the library.

The present invention relates to a novel peptide and a use thereof, and more particularly, to a peptide having a length of 12 to 20 a.a. Comprising an amino acid sequence designated as SEQ ID NO: 1 or 2, in which 1 to 4 of the amino acids other than glycine are L-type amino acids and the other amino acids are D-type amino acids, which has the ability to inhibit the formation of abnormal protein aggregates.

The invention discloses a preparation method of an Iars1 gene knockout zebrafish model, which comprises the following steps: mixing sgRNA fragments and Cas9 protein, injecting a mixed solution into zebrafish fertilized eggs in 1-2 cell stages through micro-injection, and obtaining Iars1 gene edited individuals after the fertilized eggs are hatched and cultured; after genotype identification, family screening and continuous breeding, the stably inherited Iars1 gene knockout zebrafish mutant strain is obtained. According to the invention, a zebrafish Iars1 gene is subjected to targeted editing by adopting a CRISPR / Cas9 technology, a zebrafish model carrying deletion mutation is obtained, and a stably inherited mutant is obtained through molecular identification. The model constructed by the invention can be used for researching early development abnormality related to Iars1 function deficiency, and an experimental model can be provided for evaluating early nutrition utilization abnormality, protein translation related abnormality and candidate interveners. The construction method is reliable, the model phenotype is clear, and the method has good research and application prospects.

Provided is an agent for inhibiting abnormal protein aggregate accumulation or an agent for inhibiting the uptake of an abnormal protein into a neuron, particularly an agent for preventing or treating a disease associated with accumulation of abnormal protein aggregates, in which the agent contains an RGMa inhibiting substance.

The present invention relates to a novel peptide and a use thereof, and more particularly, to a novel peptide having a length of 4 to 10 a.a. And a structure of H-G-X1-X2-G-X3, which has an ability to inhibit abnormal protein aggregate formation and autophagy activity against protein aggregates.

A variable splicing event in a gene may result in a non-productive mRNA transcript, which in turn may result in abnormal or reduced protein expression, and therapeutic agents that can target the variable splicing event in the gene can modulate the expression level of a functional protein and / or inhibit aberrant protein expression in a patient. Such therapeutic agents can be used to treat conditions or diseases caused by protein deficiency.

Provided is a prophylactic or therapeutic agent for diseases in which accumulation of abnormal protein aggregates is involved, said prophylactic or therapeutic agent comprising an RGMa inhibitor, or an inhibitor for the uptake of abnormal proteins into nerve cells.

The present invention relates to novel peptides and uses thereof, and more particularly to a novel peptides with a length of from 4 to 10 amino acids and a structure of H-G-X1-X2-G-X3, which have the ability to inhibit the formation of abnormal protein aggregates and autophagic activity against the protein aggregates.

The present invention relates to novel peptides and uses thereof, and more particularly to a novel peptide with a length of from 4 to 10 a.a. and a structure of H-G-X1 -X2 -G-X3, which have the ability to inhibit the formation of abnormal protein aggregates and autophagic activity against the protein aggregates.